https://www.selleckchem.com/products/GDC-0879.html
01 m/s, 95% CI-0.05 to 0.04), step length (MD 1.2 cm, 95% CI-1.2 to 3.5) or cadence (MD-3 steps/minute, 95% CI-6 to 1). No evidence was identified with which to estimate the effect of the addition of tDCS to walking training on freezing of gait, falls and social participation. The addition of tDCS to walking training provided no clinically important benefits on walking in ambulatory people with Parkinson's disease. PROSPERO CRD42020162908. PROSPERO CRD42020162908. What were the experiences of physiotherapists and patients who consulted
Like
Comment
Share
